TNFRSF18 and neoplasm: In an anti-PD-1 antibody resistant tumor 344SQR murine model, combination of anti-GITR antibody, anti-PD-1 antibody, and RT (3 × 12 Gy) significantly improved survival and abscopal response, with 50% of tumor-free mice [55].